CLUSTER 1

Discussion in 'Pfizer' started by Anonymous, Sep 17, 2014 at 1:19 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    What products does Cluster 1 promote? Viagra & Celebrex? You think a rural area for PHR is safe or what? Good Luck!
     

  2. Anonymous

    Anonymous Guest

    Cluster 1 will have Lyrica, Flector, and Embeda in one bag and Lyrica, Viagra, and Toviaz in the other bag. Cluster 3 will have Chantix and will only be in larger cities. Rural areas may get hurt a little more simply because there will be no Cluster 3 reps. 11% cut nationwide (current actual head count-not including vacancies) across Cluster 1/3. Some areas more, some areas less. Realistically areas/states with higher current vacancies though should be affected a little less.
     
  3. Anonymous

    Anonymous Guest

    Do you know if the LAT footprint will stay the same or if LATs/districts will combine?

    Thanks for the info
     
  4. Anonymous

    Anonymous Guest

    so what does Cluster 1 promote now? Viagra and what?
     
  5. Anonymous

    Anonymous Guest

    I don't know for sure on this. But given the percentages they gave us on the call, plus the bag makeup I don't see LAT footprints changing much if at all. My bet is that C1 territories will stay the same or very close to the same. C3 will be different simply because rural coverage will be gone.

    Again, I don't know for sure here. Just using what they gave us. It seems that the more rural areas as well as anyone who was Below Expectations in either 2012 or 2013 would be the ones who have to be the most prepared.
     
  6. Anonymous

    Anonymous Guest

    Currently C1 has Lyrica, Celebrex, Viagra, and Flector Patch
     
  7. Anonymous

    Anonymous Guest

    If the cuts total 11% + vacancies (as high as 20% nationwide) plus 27% cuts to the DM group I don't see LAT's remaining the same. Even if they cut C3 100% that wouldn't make up the %'s mentioned.

    I see LAT's combining at a rate of 2 down to 1 or 1.5 to 1 at best. How can they not?

    Cluster 3 will be shadow of itself. Chantix does just over 650m annually, and will be promoted by a 100 person sales force. Is this just a placeholder to reassure the FDA we believe in this product. We've started a large study looking at psych effects but that wont be complete until 2017. How much growth can we expect over the next 2-3 years.

    Big questions are:
    1 # of DSR's/where will they be allocated in the future
    2 Where will Pfizer decide to keep the most Reps; rural, metro, open access states, closed access states, etc.
    3 How many Reps per DM
    4 Which criteria listed will be weighed the most geo, perf. current product mix
    5 will displaced DSR's bump PHR's
    6 Will C3 Reps bump C1 Reps for the uro focus bag

    Many more ?'s for sure. If you have any ideas around these or other questions post. If you can't back up your thought process don't bother posting.
     
  8. Anonymous

    Anonymous Guest

    The previous poster was backing up his thought process...did you even listen to the conference call or were you too busy formulating your own opinion before the facts were laid out?
     
  9. Anonymous

    Anonymous Guest

    Dude, you're thinkin WAY too much into this! Simple math- if you have 50 C1/C3 reps in your state, about 6 will be gone. It's that simple. Save the overthinking stuff!
     
  10. Anonymous

    Anonymous Guest

    Killing me!

    YES...really reading more into this drama.

    The description read like a pharma package insert.

    Truly...thanks for the chuckle!

    Blessings to all!
     
  11. Anonymous

    Anonymous Guest

    The Pfizer Labs hospital rep of 1997 would cry if they knew what their progeny would be carrying in their bag 17 years later.

    1997 Zithro, Zithro IV. Zyrtec. Norvasc. Lipitor. Viagra.

    17 years later: a 16 year old drug (Celebrex), that same Viagra, and a spin-off of a PD drug that sold more for unapproved indications than for approved?

    We are a shadow of our former selves.
     
  12. Anonymous

    Anonymous Guest

    And just compare the senior sales leadership of today with a BJ Robison or a Hank McCrorie
     
  13. Anonymous

    Anonymous Guest

    My bad, I forgot I was sharing complex ideas with Pharma Reps.

    I wish you all well next month, but I think more than 6 people in your state will be cut. And as an X-DSR I hope my peers fair well in this process.
     
  14. Anonymous

    Anonymous Guest

    Who will be the 6 people cut? I think that's what the poster was trying to put together.
     
  15. Anonymous

    Anonymous Guest

    If it doesn't effect you why are you wasting your time here?
     
  16. Anonymous

    Anonymous Guest

    Wow! You think your ideas were complex? Do you think this because you spewed a bunch of stuff into the thread? Your ideas are elementary at best. Maybe take a Xanax and stop and think that the answers to your simple ideas are even more simple.
     
  17. Anonymous

    Anonymous Guest

    OK, lets look at this. DSR's ALWAYS and historically take a hit, BIG TIME! Never are they asked to replace PHR's. Too expensive to do that people!!! These PHR's make 50% less than DSR's: the newer ones, so don't reply to that statement!
     
  18. Anonymous

    Anonymous Guest

    Once again, if you are a PHR with 15 or so years tenure, you are gone! Especially if you are 45-53 yrs old! Do I need to spell this stuff out to you?
     
  19. Anonymous

    Anonymous Guest

    Not looking good.
     
  20. Anonymous

    Anonymous Guest

    Nope, they aren't as complex as this post:

    "I don't know for sure on this. But given the percentages they gave us on the call, plus the bag makeup I don't see LAT footprints changing much if at all. My bet is that C1 territories will stay the same or very close to the same. C3 will be different simply because rural coverage will be gone."

    Or your ideas:

    Oh wait you've said nothing of substance. Except your overly simple math.

    Finally, do you think you could type the simple answers to my simple questions? Didn't think so.